Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
Top Cited Papers
- 1 October 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 126-136
Abstract
Refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL) patients have poor prognoses, due to the lack of effective salvage therapies. Recently, CD7-targeting chimeric antigen receptor (CAR)-T therapies show efficacy in patients with r/r T-ALL, but relapse with CD7 loss is common. This study evaluates a CD5-gene-edited CAR-T cell therapy targeting CD5 in 19 r/r T-ALL patients, most of whom had previously failed CD7 CAR-T interventions. CAR-T products were derived from previous transplant donors (Cohort A) or newly matched donors (Cohort B). Primary endpoints were dose-limiting toxicity at 21 days and adverse events within 30 days. Secondary endpoints were responses, pharmacokinetics and severe adverse events after 30 days. A total of 16 received infusions, 10 at target dose of 1 × 106 kg−1. All encountered grade 3–4 cytopenias and one had a grade 3 infection within 30 days. All patients (100%) achieved complete remission or complete remission with incomplete blood count recovery by day 30. At a median follow-up of 14.3 months, four received transplantation; three were in remission and one died of infection. Of 12 untransplanted patients, 2 were in remission, 3 relapsed, 5 died of infection and 2 of thrombotic microangiopathy. CAR-T cells persisted and cleared CD5+ T cells. CD5− T cells, mostly CD5-gene-edited, increased but remained below normal levels. These results suggest this CD5-specific CAR-T intervention has a high remission rate for T-ALL patients. Evidence also suggests the risk of late-onset severe infection may be mitigated with consolidative transplantation. This study provides insights that could help to optimize this promising intervention. ClinicalTrials.gov registration: NCT05032599.Keywords
This publication has 41 references indexed in Scilit:
- Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic MalignancyTransplantation and Cellular Therapy, 2022
- The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domainsMolecular Therapy, 2021
- High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18Biochemical and Biophysical Research Communications, 2021
- Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL studyAmerican Journal of Hematology, 2020
- CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicityEuropean Journal of Immunology, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemiaThe Lancet Oncology, 2019
- The EBMT Handbook2019
- Early phase clinical trials to identify optimal dosing and safetyMolecular Oncology, 2014
- CD5: A safeguard against autoimmunity and a shield for cancer cellsAutoimmunity Reviews, 2009